35,000 stock options granted to Korro Bio (KRRO) Chief Scientific Officer

Rhea-AI Filing Summary

Korro Bio, Inc. reported that its Chief Scientific Officer, Vincent Loic A, received a grant of stock options on February 2, 2026. The award covers 35,000 stock options with an exercise price of $13.05 per share for Korro Bio common stock.

The options vest in 48 equal monthly installments starting on February 2, 2026, and each monthly vesting is conditioned on the executive’s continued service on that date. After this grant, the officer beneficially owns 35,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vincent Loic A

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	35,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 35,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vincent Loic A

(Last) (First) (Middle)

C/O KORRO BIO, INC.

60 FIRST STREET, 2ND FLOOR, SUITE 250

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.05	02/02/2026		A		35,000		(1)	02/01/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. The shares subject to the option vest in 48 equal monthly installments commencing from February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Jeffrey Cerio, Attorney-in-fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Korro Bio (KRRO) disclose for its Chief Scientific Officer?

Korro Bio disclosed a stock option grant to its Chief Scientific Officer. On February 2, 2026, Vincent Loic A received options for 35,000 shares of common stock at a $13.05 exercise price, reported as directly owned derivative securities.

How many stock options were granted to the Korro Bio (KRRO) Chief Scientific Officer?

The Chief Scientific Officer received 35,000 stock options. These options give the right to buy 35,000 shares of Korro Bio common stock at a $13.05 exercise price, with all 35,000 options shown as beneficially owned following the reported transaction.

What is the exercise price of the Korro Bio (KRRO) stock options granted?

The stock options have a $13.05 exercise price per share. This means the Chief Scientific Officer can purchase Korro Bio common stock at $13.05 for each of the 35,000 optioned shares, subject to the vesting schedule and continued service conditions.

How do the Korro Bio (KRRO) stock options vest for the Chief Scientific Officer?

The options vest in 48 equal monthly installments. Vesting begins on February 2, 2026, and continues monthly, with each installment requiring the Chief Scientific Officer to remain in service on the applicable vesting date for those options to vest.

Is the Korro Bio (KRRO) Chief Scientific Officer’s ownership direct or indirect?

The reported ownership of the stock options is direct. The Form 4 identifies the 35,000 derivative securities as directly owned by the Chief Scientific Officer, with no separate entity or indirect beneficial ownership structure indicated in the provided footnotes.

What type of security did Korro Bio (KRRO) report in this Form 4?

The filing reports a derivative security: a stock option. Specifically, it is a “Stock Option (Right to Buy)” for 35,000 shares of Korro Bio common stock, with a $13.05 exercise price and a monthly vesting schedule over 48 months.